Article Text

Treatment recommendations for psoriatic arthritis
  1. C T Ritchlin1,
  2. A Kavanaugh2,
  3. D D Gladman3,
  4. P J Mease4,
  5. P Helliwell5,
  6. W-H Boehncke6,
  7. K de Vlam7,
  8. D Fiorentino8,
  9. O FitzGerald9,
  10. A B Gottlieb10,
  11. N J McHugh11,
  12. P Nash12,
  13. A A Qureshi13,
  14. E R Soriano14,
  15. W J Taylor15
  1. 1
    University of Rochester Medical Center, Rochester, New York, USA
  2. 2
    University of California at San Diego, San Diego, California, USA
  3. 3
    University of Toronto, Toronto, Ontario, Canada
  4. 4
    Seattle Rheumatology Associates, Seattle, Washington, USA
  5. 5
    Academic Unit of Musculoskeletal and Rehabilitation Medicine, University of Leeds, Leeds, UK
  6. 6
    Johann Wolfgang Goethe University, Frankfurt, Germany
  7. 7
    University Hospitals Leuven, Leuven, Belgium
  8. 8
    Stanford University, Stanford, California, USA
  9. 9
    St. Vincent’s University Hospital, Dublin, Ireland
  10. 10
    Tufts Medical Center, Boston, Massachusetts, USA
  11. 11
    Royal National Hospital for Rheumatic Diseases, Bath, UK
  12. 12
    University of Queensland, Cotton Tree, Queensland, Australia
  13. 13
    Harvard Medical School, Boston, Massachusetts, USA
  14. 14
    Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
  15. 15
    University of Otago/Wellington, Wellington, New Zealand
  1. Correspondence to C T Ritchlin, Clinical Immunology Research Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, New York 14642, USA; christopher_ritchlin{at}


Objective: To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion.

Methods: Formal literature reviews of treatment for the most significant discrete clinical manifestations of PsA (skin and nails, peripheral arthritis, axial disease, dactylitis and enthesitis) were performed and published by members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations were drafted for each of the clinical manifestations by rheumatologists, dermatologists and PsA patients based on the literature reviews and consensus opinion. The level of agreement for the individual treatment recommendations among GRAPPA members was assessed with an online questionnaire.

Results: Treatment recommendations were developed for peripheral arthritis, axial disease, psoriasis, nail disease, dactylitis and enthesitis in the setting of PsA. In rotal, 19 recommendations were drafted, and over 80% agreement was obtained on 16 of them. In addition, a grid that factors disease severity into each of the different disease manifestations was developed to help the clinician with treatment decisions for the individual patient from an evidenced-based perspective.

Conclusions: Treatment recommendations for the cardinal physical manifestations of PsA were developed based on a literature review and consensus between rheumatologists and dermatologists. In addition, a grid was established to assist in therapeutic reasoning and decision making for individual patients. It is anticipated that periodic updates will take place using this framework as new data become available.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials